Dorit Fabricius

TL;DR: These findings establish the existence of human B cells with a regulatory phenotype in solid tumor infiltrates, where they may contribute to the suppression of antitumor immune responses and stimulate novel diagnostic and cell therapeutic approaches to better manage human cancer as well as autoimmune and graft-versus-host pathologies.

TL;DR: It is demonstrated that human plasmacytoid dendritic cells can be an abundant source of GrB and that such GrB(+) pDCs potently suppress T-cell proliferation in a GrB-dependent, perforin-independent manner, a process reminiscent of regulatory T cells.

TL;DR: These findings suggest that GrB-secreting B cells support the early antiviral immune response against viruses with endosomal entry pathways, thereby counteracting overwhelming viral replication at the beginning of an infection until virus-specific T cells from draining lymph nodes arrive at the site of infection.

TL;DR: It is shown that in the absence of CD40L, CD4+ T cell‐derived IL‐21 induces differentiation of B cells into granzyme B (GzmB)‐secreting cytotoxic cells, which may have a role in early cellular immune responses including tumor immunosurveillance before fully activated, antigen‐specific cytot toxic T cells are on the spot.

TL;DR: The data suggest that PGE2 and certain PG analogs should be evaluated as a novel and inexpensive treatment approach for patients with SLE and other IFN-α–dependent, Th1-driven autoimmune diseases.